Mithilesh Kumar Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mithilesh Kumar Das has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Jo Mahenthiran
5 shared publications- Douglas P. Zipes
Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana
4 shared publications Gopi Dandamudi
Krannert Institute of Cardiology, Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, Indiana
4 shared publicationsChangyu Shen
3 shared publications- Hussam S. Suradi
Division of Cardiology, Rush University Medical Center, Chicago, IL (H.S.S.).
3 shared publications Jonathan Peng
3 shared publications
Latest Publications
- 23 October 2018
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 29 (5) , 272-273
Editorial commentary: Luminal esophageal temperature monitoring during catheter ablation of atrial fibrillation to prevent atrio-eophagial fistula: What we have learned so far to prevent this dreaded complication?
- 23 October 2018
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 29 (5) , 272-273
Editorial commentary: Luminal esophageal temperature monitoring during catheter ablation of atrial fibrillation to prevent atrio-eophagial fistula: What we have learned so far to prevent this dreaded complication?
- 1 January 2018
- Published by Elsevier
- p. 567-573
Differential Diagnosis of Narrow and Wide Complex Tachycardias
- 1 January 2018
- Published by Elsevier
- p. 567-573
Differential Diagnosis of Narrow and Wide Complex Tachycardias
- Open Access
- 1 May 2015
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 1 (3) , 117-119
Social anxiety provoked by speech-induced atrial tachycardia
- 1 May 2015
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 1 (3) , 117-119
Open AccessSocial anxiety provoked by speech-induced atrial tachycardia
- Open Access
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 10 (3) , 277-286
Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Various noninvasive tests for risk stratification of sudden cardiac death (SCD) were studied, mostly in the context of structural heart disease such as coronary artery disease (CAD), cardiomyopathy and heart failure but have low positive predictive value for SCD. Fragmented QRS complexes (fQRS) on a 12-lead ECG is a marker of depolarization abnormality. fQRS include presence of various morphologies of the QRS wave with or without a Q wave and includes the presence of an additional R wave (R’) or notching in the nadir of the R’ (fragmentation) in two contiguous leads, corresponding to a major coronary artery territory. fQRS represents conduction delay from inhomogeneous activation of the ventricles due to myocardial scar. It has a high predictive value for myocardial scar and mortality in patients CAD. fQRS also predicts arrhythmic events and mortality in patients with implantable cardioverter defibrillator. It also signifies poor prognosis in patients with nonischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome. However, fQRS is a nonspecific finding and its diagnostic prognostic should only be interpreted in the presence of pertinent clinical evidence and type of myocardial involvement (structural vs. structurally normal heart).
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 10 (3) , 277-286
Open AccessFragmented ECG as a Risk Marker in Cardiovascular Diseases
Various noninvasive tests for risk stratification of sudden cardiac death (SCD) were studied, mostly in the context of structural heart disease such as coronary artery disease (CAD), cardiomyopathy and heart failure but have low positive predictive value for SCD. Fragmented QRS complexes (fQRS) on a 12-lead ECG is a marker of depolarization abnormality. fQRS include presence of various morphologies of the QRS wave with or without a Q wave and includes the presence of an additional R wave (R’) or notching in the nadir of the R’ (fragmentation) in two contiguous leads, corresponding to a major coronary artery territory. fQRS represents conduction delay from inhomogeneous activation of the ventricles due to myocardial scar. It has a high predictive value for myocardial scar and mortality in patients CAD. fQRS also predicts arrhythmic events and mortality in patients with implantable cardioverter defibrillator. It also signifies poor prognosis in patients with nonischemic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome. However, fQRS is a nonspecific finding and its diagnostic prognostic should only be interpreted in the presence of pertinent clinical evidence and type of myocardial involvement (structural vs. structurally normal heart).
- Open Access
- 1 January 2014
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 44 (4) , 271-273
Supraventricular Tachycardia and Sinus Rhythm with Contralateral Bundle Branch Block Patterns
Han S, et al. Korean Circ J. 2014 Jul;44(4):271-273. http://dx.doi.org/10.4070/kcj.2014.44.4.271
- 1 January 2014
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 44 (4) , 271-273
Open AccessSupraventricular Tachycardia and Sinus Rhythm with Contralateral Bundle Branch Block Patterns
Han S, et al. Korean Circ J. 2014 Jul;44(4):271-273. http://dx.doi.org/10.4070/kcj.2014.44.4.271
- 1 May 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 55 (5) , 438-449
Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention
Life-threatening ventricular arrhythmias such as sustained ventricular tachycardia and ventricular fibrillation are responsible for two thirds of sudden cardiac deaths annually in the United States. Implantable cardioverter-defibrillator (ICD) therapy prevents mortality from arrhythmic death but is expensive and has some associated morbidity from proarrhythmia and mechanical malfunction. Furthermore, ICDs treat ventricular arrhythmias but do not prevent them. Antiarrhythmic drugs (AADs) can be used for acute or chronic therapy to prevent ventricular arrhythmias and sudden cardiac deaths. AADS are often used in patients with an ICD who have recurrent ICD shocks resulting from ventricular arrhythmias. Class I AADs are contraindicated in patients with structural heart disease. Other than amiodarone, all Class III drugs have either a neutral or deleterious effect on mortality. Dronedarone, a new Class III drug, may reduce mortality, but more information is needed to be sure. A class of drugs that do not qualify as an AAD can modify cardiovascular remodeling processes and have a delayed and indirect antiarrhythmic effect. These so-called "nonantiarrhythmic drugs" such as drugs acting on the renin-angiotensin-aldosterone system, fish oil, and statins can reduce the likelihood of future ventricular tachycardia/ventricular fibrillation in patients with coronary artery disease or congestive heart failure. The role of AADs for chronic therapy for primary and secondary prevention of sudden cardiac death is problematic because of proarrhythmia and adverse side effects. Because these nonantiarrhythmic drugs are well tolerated and have no proarrhythmic actions, their benefits should outweigh risks.
- 1 May 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 55 (5) , 438-449
Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention
Life-threatening ventricular arrhythmias such as sustained ventricular tachycardia and ventricular fibrillation are responsible for two thirds of sudden cardiac deaths annually in the United States. Implantable cardioverter-defibrillator (ICD) therapy prevents mortality from arrhythmic death but is expensive and has some associated morbidity from proarrhythmia and mechanical malfunction. Furthermore, ICDs treat ventricular arrhythmias but do not prevent them. Antiarrhythmic drugs (AADs) can be used for acute or chronic therapy to prevent ventricular arrhythmias and sudden cardiac deaths. AADS are often used in patients with an ICD who have recurrent ICD shocks resulting from ventricular arrhythmias. Class I AADs are contraindicated in patients with structural heart disease. Other than amiodarone, all Class III drugs have either a neutral or deleterious effect on mortality. Dronedarone, a new Class III drug, may reduce mortality, but more information is needed to be sure. A class of drugs that do not qualify as an AAD can modify cardiovascular remodeling processes and have a delayed and indirect antiarrhythmic effect. These so-called "nonantiarrhythmic drugs" such as drugs acting on the renin-angiotensin-aldosterone system, fish oil, and statins can reduce the likelihood of future ventricular tachycardia/ventricular fibrillation in patients with coronary artery disease or congestive heart failure. The role of AADs for chronic therapy for primary and secondary prevention of sudden cardiac death is problematic because of proarrhythmia and adverse side effects. Because these nonantiarrhythmic drugs are well tolerated and have no proarrhythmic actions, their benefits should outweigh risks.
- 1 March 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (3) , 305-311
Focal mechanism of ventricular tachycardia in coronary artery disease
- 1 March 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (3) , 305-311
Focal mechanism of ventricular tachycardia in coronary artery disease
- 1 January 2010
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 25 (1) , 59-64
Fragmented QRS and other depolarization abnormalities as a predictor of mortality and sudden cardiac death
Several invasive and noninvasive tests for risk stratification of sudden cardiac death (SCD) have been studied. Tests such as microwave T wave alternans (repolarization abnormality) and signal-averaged ECG (depolarization abnormality) have high negative predictive values but low positive predictive values in patients with heart disease. The presence of a fragmented QRS (fQRS) complex on a routine 12-lead ECG is another marker of depolarization abnormality. The purpose of this review is to discuss the potential utility of tests to detect depolarization abnormalities of the heart for the risk stratification of mortality and SCD with main emphasis on fQRS. fQRS is associated with increased mortality and arrhythmic events in patients with coronary artery disease. fQRS has also been defined as a marker of arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome. In Brugada syndrome, the presence of fQRS predicts episodes of ventricular fibrillation during follow-up. fQRS may be of value in determining the risk for SCD and guiding selection for device therapy in patients with structural heart disease and Brugada syndrome. It is possible that the predictive value of fQRS for SCD can be enhanced further by combining a marker of repolarization abnormality such as microwave T wave alternans.
- 1 January 2010
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 25 (1) , 59-64
Fragmented QRS and other depolarization abnormalities as a predictor of mortality and sudden cardiac death
Several invasive and noninvasive tests for risk stratification of sudden cardiac death (SCD) have been studied. Tests such as microwave T wave alternans (repolarization abnormality) and signal-averaged ECG (depolarization abnormality) have high negative predictive values but low positive predictive values in patients with heart disease. The presence of a fragmented QRS (fQRS) complex on a routine 12-lead ECG is another marker of depolarization abnormality. The purpose of this review is to discuss the potential utility of tests to detect depolarization abnormalities of the heart for the risk stratification of mortality and SCD with main emphasis on fQRS. fQRS is associated with increased mortality and arrhythmic events in patients with coronary artery disease. fQRS has also been defined as a marker of arrhythmogenic right ventricular cardiomyopathy and Brugada syndrome. In Brugada syndrome, the presence of fQRS predicts episodes of ventricular fibrillation during follow-up. fQRS may be of value in determining the risk for SCD and guiding selection for device therapy in patients with structural heart disease and Brugada syndrome. It is possible that the predictive value of fQRS for SCD can be enhanced further by combining a marker of repolarization abnormality such as microwave T wave alternans.
- 1 January 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (1) , 74-80
Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy
- 1 January 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (1) , 74-80
Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy
- 1 January 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (1) , 88-95
Mechanisms of sinoatrial node dysfunction in a canine model of pacing-induced atrial fibrillation
- 1 January 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (1) , 88-95
Mechanisms of sinoatrial node dysfunction in a canine model of pacing-induced atrial fibrillation